Preliminary EvidenceResearch OnlyWADA Prohibited

MOTS-c: What the Research Shows

Also known as: Mitochondrial Open Reading Frame of the 12S rRNA-c

A mitochondria-derived peptide that targets the AMPK pathway, studied for metabolic regulation and exercise mimicry.

This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer

Quick Facts

Category🔥 Metabolic
Amino Acids16
Molecular Weight2174.69 Da
FormulaC101H152N28O22S2
FDA StatusResearch Only
Evidence RatingPreliminary
Human TrialsNo
WADA StatusProhibited (since 2022)
Routessubcutaneous
Last Reviewed2026-03-11

Regulatory Status

Not FDA-approved. Research compound. A mitochondria-derived peptide discovered in 2015.

Researched Applications

Metabolic regulationExercise mimicryInsulin sensitivityLongevity

Key Research (1 studies cited)

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

animal

Reynolds JC, et al. (2021) — Nature Communications

Study showing MOTS-c levels increase with exercise and administration improves physical capacity in aged mice.

Key finding: MOTS-c treatment improved physical performance and muscle homeostasis in aged mice, mimicking some effects of exercise.

PubMed: 33420028

About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer

Compare MOTS-c

See how MOTS-c compares to similar compounds.

Open comparison tool →

The Peptide Brief

Weekly peptide research digest. No spam.

Last reviewed: 2026-03-11